BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38507067)

  • 1. Identification of a novel ADCC-related gene signature for predicting the prognosis and therapy response in lung adenocarcinoma.
    Zhang L; Zhang X; Guan M; Zeng J; Yu F; Lai F
    Inflamm Res; 2024 May; 73(5):841-866. PubMed ID: 38507067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine-learning developed an iron, copper, and sulfur-metabolism associated signature predicts lung adenocarcinoma prognosis and therapy response.
    Zhang L; Zhang X; Guan M; Zeng J; Yu F; Lai F
    Respir Res; 2024 May; 25(1):206. PubMed ID: 38745285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-depth single-cell and bulk-RNA sequencing developed a NETosis-related gene signature affects non-small-cell lung cancer prognosis and tumor microenvironment: results from over 3,000 patients.
    Zhang L; Zhang X; Guan M; Yu F; Lai F
    Front Oncol; 2023; 13():1282335. PubMed ID: 37927467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
    Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
    Shu J; Jiang J; Zhao G
    Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
    Liang H; Li Y; Qu Y; Zhang L
    Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts.
    Ren Q; Zhang P; Lin H; Feng Y; Chi H; Zhang X; Xia Z; Cai H; Yu Y
    Front Immunol; 2023; 14():1201573. PubMed ID: 37325647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine Learning-Based Integration Develops a Macrophage-Related Index for Predicting Prognosis and Immunotherapy Response in Lung Adenocarcinoma.
    Li Z; Guo M; Lin W; Huang P
    Arch Med Res; 2023 Nov; 54(7):102897. PubMed ID: 37865004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
    Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
    Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
    Tang X; Zhou H; Liu Y
    Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The integrated single-cell analysis developed an immunogenic cell death signature to predict lung adenocarcinoma prognosis and immunotherapy.
    Zhang P; Zhang H; Tang J; Ren Q; Zhang J; Chi H; Xiong J; Gong X; Wang W; Lin H; Li J; Huang C
    Aging (Albany NY); 2023 Oct; 15(19):10305-10329. PubMed ID: 37796202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
    Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
    BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying an immunogenic cell death-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma.
    Li X; Zhang D; Guo P; Ma S; Gao S; Li S; Yuan Y
    Aging (Albany NY); 2024 Apr; 16(7):6290-6313. PubMed ID: 38575204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-cell dissection reveals the role of aggrephagy patterns in tumor microenvironment components aiding predicting prognosis and immunotherapy on lung adenocarcinoma.
    Sun X; Meng F; Nong M; Fang H; Lu C; Wang Y; Zhang P
    Aging (Albany NY); 2023 Dec; 15(23):14333-14371. PubMed ID: 38095634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
    Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
    Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.
    Bao X; Shi R; Zhao T; Wang Y
    J Mol Med (Berl); 2020 Jun; 98(6):805-818. PubMed ID: 32333046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A programmed cell death-related model based on machine learning for predicting prognosis and immunotherapy responses in patients with lung adenocarcinoma.
    Zhang Y; Wang Y; Chen J; Xia Y; Huang Y
    Front Immunol; 2023; 14():1183230. PubMed ID: 37671155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.